CancerFax
Genetic Metabolic Disorder

Understanding Methylmalonic Acidemia

An inherited organic acid disorder that impairs the breakdown of certain proteins and fats, leading to a toxic buildup of methylmalonic acid. Early diagnosis and dietary/medical management help reduce the risk of serious metabolic crises.

  • Autosomal Recessive Inheritance
  • Detected via Newborn Screening
  • Managed with Diet and Specialist Care
Estimated Incidence
1 in 50,000–100,000 births
Inheritance Pattern
Autosomal Recessive
Genes Involved
MUT, MMAA, MMAB
Typical Onset
Early Infancy
Specialist Access
Metabolic Genetics Coordination

Condition Overview

Methylmalonic acidemia (MMA) is a group of inherited disorders in which the body cannot properly process certain amino acids and fats, leading to a buildup of methylmalonic acid and other toxic byproducts. It most commonly results from mutations in the MUT gene, which encodes the enzyme methylmalonyl-CoA mutase, or from genes involved in vitamin B12 (cobalamin) metabolism, such as MMAA and MMAB.

The accumulated organic acids can affect the brain, kidneys, and bone marrow, and can trigger life-threatening metabolic crises, particularly during infancy or periods of physiological stress such as illness or fasting.

Types and Variants

Methylmalonic acidemia includes several genetically distinct subtypes with differing severity and treatment response.

Symptoms and Signs

Symptoms often appear in the first days to weeks of life, though milder forms may present later in childhood.

Causes and Risk Factors

Methylmalonic acidemia results from inherited mutations affecting enzymes or cofactor pathways needed to metabolize certain amino acids and fats.

Diagnosis and Investigations

Diagnosis combines newborn screening, biochemical testing, and genetic confirmation.

Severity Classification

Methylmalonic acidemia is classified by enzyme subtype, vitamin B12 responsiveness, and clinical severity rather than a cancer-style staging system.

Standard Management

Management focuses on preventing metabolic crises through dietary control and prompt treatment of decompensation.

Emerging Approaches and Research

Beyond standard dietary management, several advanced options are used in select cases, with further options under research.

  • Organ Transplantation

    Liver or Combined Liver-Kidney Transplantation

    Considered in select severe cases to reduce metabolite production and address kidney complications, though it does not cure the underlying enzyme defect.

    Available
  • Gene Therapy Research

    Investigational Gene/mRNA-Based Approaches

    Early-stage research is exploring gene and mRNA therapies targeting the MUT enzyme pathway.

    Investigational

Biomarkers & Laboratory Monitoring

Several biochemical markers are used for diagnosis and ongoing monitoring.

When to Seek a Second Opinion

Families may consider a specialist second opinion in several situations.

Research and Clinical Studies

Prognosis & Outlook

Prognosis depends heavily on the specific genetic subtype, vitamin B12 responsiveness, and how early treatment begins.

Supportive Care

Comprehensive supportive care helps families manage day-to-day needs and long-term complications.

How CancerFax Helps You Explore Treatment Options

CancerFax can help families coordinate medical report review and connect with metabolic genetics specialists experienced in managing methylmalonic acidemia.

Get a free case review

Frequently Asked Questions

Methylmalonic acidemia is an inherited disorder that impairs the breakdown of certain proteins and fats, leading to a buildup of methylmalonic acid that can affect the brain, kidneys, and other organs.

Need Guidance on a Methylmalonic Acidemia Diagnosis?

CancerFax can help you review medical reports and connect with metabolic specialists for further evaluation.